N-蛋白疫苗对COVID-19有效:3期,随机,双盲,安慰剂控制的临床试验

Sevastyan O Rabdano1, Ellina A Ruzanova1, Anastasiya E Vertyachikh1

  • 1Saint Petersburg Scientific Research Institute of Vaccines and Serums of the Federal Medical-Biological Agency of Russia (SPbSRIVS), Saint Petersburg, Russia.

The Journal of infection
|September 28, 2024
PubMed
概括

一种新的核体 (N) 蛋白COVID-19疫苗显示,对症状感染的有效性为85.2%. 这种N蛋白疫苗为针对SARS-CoV-2变种的更广泛保护提供了有希望的替代方案.